6681.HK

BrainAurora Medical Tech Ltd. (6681.HK) announced on Friday that its CEO and chief research officer Wang Xiaoyi resigned, effective Thursday, due to health issues caused by worsening depression.

The company said that Wang’s condition deteriorated during its IPO process, and he has decided to suspend all work to focus on treatment and recovery. It added the decision also helps ensure stable corporate governance. CTO and COO Cai Longjun will assume Wang’s duties.

Based in the city of Shaoxing in East China’s Zhejiang province, BrainAurora says it is China’s first company to integrate neuroscience and AI to develop medical-grade digital therapeutics. Its product pipeline spans vascular diseases, neurodegenerative conditions, mental health disorders and developmental disorders in children. Last year the company’s revenue rose 82% to 122 million yuan ($17 million), while its net loss narrowed 44.7% to 198 million yuan.

The company’s stock opened higher on Friday after the announcement and closed at HK$ 6.99 by the midday break, up 1.8%.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of China's hydrogen battery industry

China plays defense on EV batteries, offense on hydrogen

China rolls out new rules restricting the export of cutting-edge technology for EV battery manufacturing. How will this affect Chinese battery makers setting up factories abroad? And hydrogen fuel cell maker Refire reports its revenue fell 10% in the first half of the year. What does this say about a Chinese sector that's getting huge government support, but has yet to find a mass audience?